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The 2015 World Health Organization (WHO) Guidelines on
when to start antiretroviral (ARV) therapy and on pre-
exposure prophylaxis (PrEP) for HIV [1] made two landmark
recommendations: 1) the offer of ARV treatment to anybody
diagnosed with HIV infection, regardless of CD4 levels (i.e.
‘‘test and offer’’); and 2) the offer of oral HIV PrEP with a
tenofovir-containing scheme to any person at substantial
risk. As of mid-2016, many of the concerns about potential
roll-out that emerged from clinical trials are quickly fading:
real-life effectiveness has been demonstrated in 2015/2016
and qualified the role of some of the important undesired
occurrences that had been anticipated such as low adherence
and ‘‘risk compensation’’ leading to viral resistance and new
infections [2]. Studies such as PROUD [3] have shown that
at least men who have sex with men (MSM) who use PrEP are
at significant risk (due to frequent condomless anal inter-
course with casual partners of unknown serostatus), are highly
adherent, and can benefit from PrEP effectiveness. PrEP up-
take with high adherence in certain communities (e.g. the gay
community in San Francisco) [4] is contributing to significant
reductions in HIV infections in that city. In addition, studies
assessing intermittent PrEP (e.g. the on-demand PrEP scheme
used in Ipergay [5], and alternative schemes for MSM included
in a Thai study) have also contributed exciting results [6].
On 8 June 2016, the UN General Assembly signed the po-
litical declaration on HIV and AIDS: on the fast-track to
accelerate the fight against HIV and to end the AIDS epidemic
by 2030 [7].To fulfill the aspirations of the political declaration,
UNAIDS has established a 20162021 strategy [8] with targets
set in HIV prevention and care at the local and regional levels:
an ambitious target of ensuring access to PrEP for threemillion
people at substantial risk by 2020. This is based on reaching
an overall estimate of 10% of populations at increased risk,
namely key populations including MSM, transgender people,
and sex workers as well as young women of reproductive age
living in the most highly affected communities and people
in serodiscordant partnerships where the viral load of the
positive partner is not known to be reliably suppressed.
Despite recent progress and these aspirational goals, actual
roll-out at a global scale is just beginning, and considerable
challenges remain unmet. The planning and organization
of demonstration studies beyond MSM in the United States
and the UK has been slow, and implementation-relevant
information for both the general population and specific key
populations (e.g. female sex workers in generalized epidemic
contexts, and MSM and transwomen in Asia and Latin
America) is still lacking. While concerns about adherence
and effectiveness (particularly among MSM) have abated,
some other issues have emerged, including 1) the preferred
ARV agent, although tenofoviremtricitabine is the only
licensed agent at present; 2) potential of less frequent dosing,
cost and sustainability (as much in lower-middle income as in
higher-income countries); and 3) a long list of implementation
questions that vary by setting and target population. The latter
may make monitoring of impact and outcome more complex.
NEMUS, in collaboration with UNAIDS, has followed its
first supplement on PrEP beyond clinical trials [9] with this
new collection of papers focused on PrEP roll-out, identifying
barriers and solutions, again with a focus on regions and popu-
lations not considered before. In this editorial, we highlight
the main messages of the papers included in this new series.
Together with other tools that will be published soon, such as
the upcoming WHO implementation guidelines, this publication
will help to document progress and guide implementers through
a rapidly changing field.
Contributions included in this special issue
A paper by Ca´ceres et al. [9] discusses PrEP scale-up to date,
including the observed levels of access and policy develop-
ment, and elaborates on key emerging policy and research
issues to consider for further roll-out, with a special focus on
lower-middle income countries.While feasibility, acceptability
and potential impact have been demonstrated, creative solu-
tions will be needed to overcome challenges, which include
operational and health systems barriers, drug cost and re-
gulatory policies, health providers’ openness to prescribing
PrEP to populations at substantial risk, demand creation and
legal and human rights issues.
The contribution by McGillen et al. [10] examines what role
PrEP should play in an optimal patterning of combination
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prevention in the complex and dynamic landscape of sub-
Saharan Africa. The authors use a previously described mathe-
matical model and focus on PrEP to explore how best to
distribute PrEP within broader prevention resources. They
propose that if current year-on-year financial contributions to
prevention funding were to be maintained, an incidence
benchmark, as per the new WHO guidelines, would serve as
a reasonable way to determine where and to whom PrEP
should be offered.
Also focusing on sub-Saharan Africa, Cowan et al. [11] state
that at least 3 million individuals in Africa are likely to be
eligible for PrEP according to WHO’s criteria and that several
African countries have already approved guidelines for PrEP
for individuals at substantial risk of HIV as part of combination
HIV prevention, but key questions remain about how to
identify and deliver PrEP to those at greatest need. Over-
arching issues in each of the target populations remain, such
as creating demand for PrEP, addressing supply-side issues
and providing appropriate and tailored adherence support.
Some key action areas identified included the normalization
of HIV prevention to help demand creation; community level
interventions involving opinion leaders as well as empower-
ment interventions for those at highest risk; access to quality
services for all, including for stigmatized populations; and
provision of adherence support that recognizes social and
structural factors. They predict that combining interventions
that build self-efficacy, empowerment and social cohesion is
most likely to be effective in PrEP provision.
A paper by Zablotska-Manos et al. [12] discusses the
progress towards PrEP implementation in the Asia/Pacific
region. In this region, key PrEP implementation barriers
include poor knowledge about and limited access to PrEP,
weak or non-existent HIV prevention programmes for MSM
and other key populations, high cost of PrEP, stigma and
discrimination against key populations, and restrictive laws.
While trials and implementation research is taking place only
in Thailand and Australia, novel approaches to PrEP imple-
mentation have emerged (such as researcher-, facility- and
community-led models of care, with PrEP services for fee and
for free), and there is growing community interest in PrEP in
the region. They conclude that countries in the Asia/Pacific
region will benefit from adding PrEP to their prevention
packages, but this will need investment.
Ravasi et al. [13] discuss the barriers encountered and
potential solutions needed for a fair consideration of PrEP
as part of combination HIV prevention strategies in Latin
America. No Latin American country has yet implemented a
PrEP programme, and so first steps including education of
policy makers, programmatic guidance and costing models are
still needed. Providers are not prescribing PrEP due to a lack of
national policies and guidelines and lack of training. Encoura-
gingly, key populations (MSM, transgender women (TW) and
sex workers) have participated in demonstration projects and
show high awareness and willingness to use PrEP, especially if
accessible in the public sector for free or at affordable price.
As in many regions, concerns about safety, adherence, effec-
tiveness and risk compensation need to be addressed through
targeted social communication strategies. The authors con-
clude that an alliance between policy makers, civil society
and representatives from key populations, healthcare provi-
ders and researchers will kick-start implementation of PrEP
demonstration projects and other steps needed for the suc-
cessful roll-out of PrEP in Latin America.
The final regional paper by McCormack et al. [14] focuses
on Europe, where PrEP is only available in France to date. In
a region with considerable differences in health systems and
government commitment to HIV prevention and care, the
number of HIV infections is increasing, even in countries with
free access to screening and treatment, among MSM and
other key populations. As in many parts of the world, pre-
vention funding is a fraction of care funding. Standards of care
are generally good in Western Europe, but less satisfactory in
Eastern Europe and central Asia, given limited national health
budgets and diminishing foreign aid. Even in Western Europe’s
high-income countries, the cost of Truvada† is a major barrier
to PrEP implementation, together with inadequate health
systems and a weakening civil society.
This special issue includes three papers focused on specific
populations. One contribution by Sevelius et al. [15] focuses
on TW, one of the key populations most affected by HIV, and
discusses unique considerations for maximizing the impact of
PrEP in this vulnerable population. They report that, to date,
PrEP demonstration projects and clinical trials have largely
excluded TW, or failed to include them in a meaningful way,
limiting the ability of such studies to draw conclusions about
TW’s unique needs and devise strategies to meet them. The
need for gender affirming services to facilitate the provision
of PrEP to TW is critical. There is a need to engage trans
communities, utilize trans-inclusive research and marketing
strategies, and identify and/or train health care providers to
provide gender affirming health care to trans women; in turn,
health systems must consider and address TW’s unique
barriers and facilitators to uptake and adherence.
Hosek et al. [16] focus on the potential role of PrEP among
young people and discuss data from the United States and
South Africa on the use of oral PrEP for HIV prevention in
adolescent minors, along with some of the implementation
challenges and potential strategies to address those chal-
lenges. Adolescents and young adults less than 25 years of age
in many geographical settings meet the definition of a key
population in the HIV epidemic, with very high HIV incidence
rates and limited access to prevention services. Completed
and ongoing studies in the United States and South Africa
among youth under age 18 should provide the safety data
needed by the end of 2016 to contribute to licensure of
Truvada† as daily PrEP in adolescents. A number of general
and unique challenges have arisen in this age group. Prime
among these is adherence to daily medication, which is par-
ticularly challenging among younger populations, but other
individual level barriers (e.g. limited familiarity with ARV-
based prevention, stigma, product storage and social support)
and structural challenges (e.g. healthcare financing for PrEP,
clinician acceptability and comfort with PrEP delivery, and limi-
ted youth-friendly health services available) are also described.
In turn, Coleman and McLean [17] provide a discussion
on the value of PrEP in HIV epidemics among people who
use drugs (PWUD). While PWUD are at significant risk for HIV
in many parts of the world and should be offered PrEP
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according to current recommendations, the actual feasibility
of this strategy may require an enabling legal and policy en-
vironment for delivery of health services to those in need. The
need to address structural barriers to services and human
rights violations, and to improve access to comprehensive
harm reduction programmes are of prime importance and
may have higher value than a single focus on HIV prevention,
is argued by the authors. If those conditions are not met,
shifts in funding priorities, for example, to include PrEP, could
threaten programme comprehensiveness, hence facing op-
position by PWUD. Nevertheless, nuanced needs of sub-
populations of PWUD and their partners must be explored. As
for all key populations, the involvement of PWUD in shaping
comprehensive services is vital and too often ignored.
Finally, Cairns and Race [18] present a community view-
point, which reminds the readers that PrEP has been and con-
tinues to be an intervention causing controversy and debate
between providers, advocates and potential users. Such con-
troversies, they sustain, extend beyond access and can be
related to contemporary tensions: medical risk versus benefit;
trust versus distrust of healthcare interventions; and individual
responsibility versus community cohesion. In that sense, PrEP
might lead people to perceive a risk of losing control over any
of those tensions. They close by suggesting that the develop-
ment of greater community ‘‘ownership’’ of PrEP and con-
comitant improvements in the sense of individual agency over
sexual risk might reduce the insecurities derived from those
tensions and facilitate a more neutral uptake of this strategy.
Given the need presented in this series and the promise
and potential of the clinical trials and recommendations from
WHO, it is hoped that we will see an impressive expansion of
combination prevention including PrEP in the next 25 years.
With just 14 short years before the UNAIDS target to end AIDS
by 2030, unless we urgently, actively and extensively deploy
all of the effective interventions at our disposal, this goal will
slip away from our grasp. No one should be left behind [19].
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